Calithera Biosciences (NASDAQ:CALA) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Calithera Biosciences (NASDAQ:CALA – Get Rating) in a report released on Monday morning. The brokerage issued a hold rating on the biotechnology company’s stock.

Calithera Biosciences Trading Up 4.3 %

CALA stock opened at $0.37 on Monday. The company has a market capitalization of $1.78 million, a P/E ratio of -0.01 and a beta of 1.18. Calithera Biosciences has a twelve month low of $0.01 and a twelve month high of $5.10. The business has a 50 day simple moving average of $0.07 and a 200-day simple moving average of $0.83.

Hedge Funds Weigh In On Calithera Biosciences

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. grew its position in Calithera Biosciences by 23.4% in the 3rd quarter. Vanguard Group Inc. now owns 141,217 shares of the biotechnology company’s stock valued at $415,000 after buying an additional 26,800 shares during the last quarter. Renaissance Technologies LLC grew its position in Calithera Biosciences by 13.8% in the 3rd quarter. Renaissance Technologies LLC now owns 114,555 shares of the biotechnology company’s stock valued at $337,000 after buying an additional 13,855 shares during the last quarter. Alyeska Investment Group L.P. purchased a new position in Calithera Biosciences in the 1st quarter valued at $404,000. Goldman Sachs Group Inc. boosted its position in shares of Calithera Biosciences by 143.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 123,739 shares of the biotechnology company’s stock worth $50,000 after purchasing an additional 72,865 shares in the last quarter. Finally, Affinity Asset Advisors LLC purchased a new stake in shares of Calithera Biosciences during the 1st quarter worth $404,000. 33.73% of the stock is currently owned by hedge funds and other institutional investors.

Calithera Biosciences Company Profile

(Get Rating)

Calithera Biosciences, Inc is a clinical stage precision oncology biopharmaceutical company, which engages in developing targeted therapies to redefine treatment for biomarker-specific patient populations. It also focuses on researching small molecule oncology compounds with a biomarker-driven approach that targets genetic vulnerabilities in cancer cells to deliver new therapies for patients suffering from aggressive hematologic.